Proteins and Peptides

07 Mar 2008 Alkermes Provides Update on Inhaled Insulin Program
07 Mar 2008 AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
07 Mar 2008 Lilly Announces Termination of AIR Insulin Program
06 Mar 2008 PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
06 Mar 2008 CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
05 Mar 2008 Biovitrum and Syntonix set to begin phase I/IIa clinical trial of long-acting recombinant Factor IXFc for the treatment of Hemophilia B
05 Mar 2008 Chemokine Therapeutics Receives Approval From Health Canada to Commence Phase II Study in Liver Cancer
05 Mar 2008 EU Commission Approves Updated Prescribing Information for Aranesp(R)
03 Mar 2008 Juvista Phase II Trial Results in Scar Revision and Breast Augmentation Surgery
03 Mar 2008 Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease
29 Feb 2008 OrthoLogic Announces Initiation of Dosing for AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring
28 Feb 2008 PAION's anticoagulant Solulin successfully tested in first-in-man study
28 Feb 2008 Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
28 Feb 2008 Savient Provides Further Information on Top Line Phase 3 Trials Results for Puricase(R) (pegloticase)
26 Feb 2008 Agennix's Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer
26 Feb 2008 Allon's Phase II clinical trial shows statistically significant efficacy on human cognition and memory
22 Feb 2008 FORSTEO(R) Receives Positive Opinion from the European Committee for Medicinal Products for Human Use for the Treatment of Glucocorticoid-Induced Osteoporosis
22 Feb 2008 Artisan Pharma's Lead Product, ART-123, Approved in Japan
21 Feb 2008 Wyeth's XYNTHA Approved by FDA for Treatment of Hemophilia A
20 Feb 2008 Antisense Therapeutics Ltd Licenses ATL1102 to Teva Pharmaceutical Industries Ltd.
20 Feb 2008 ConjuChem Initiates Phase II Study of PC-DAC(TM):Exendin-4
20 Feb 2008 Stem Cell Therapeutics Announces Favorable Results From the Phase IIa BETAS Stroke Trial
14 Feb 2008 Cytheris Announces 48-Week Results of Phase I/II Study Showing Administration of Interleukin-7 (IL-7) Significantly Improves CD4 T-Cell Counts in Chronically Infected HIV-1 Patients
13 Feb 2008 Unigene Announces Publication of Initial Results of Site-Directed Bone Growth Studies
12 Feb 2008 Æterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up